新華製藥(000756.SZ):在研產品包括OAB14(用於阿爾茨海默病治療)等多個1類創新藥物進展順利
格隆匯6月11日丨新華製藥(000756.SZ)在互動平臺表示,公司圍繞心腦血管類、解熱鎮痛類、消化系統類、抗代謝類、神經系統、精麻藥品等方向開展研發工作,包括創新藥物和仿製藥。進入研發管線的藥物有100多個。在創新藥領域已構建多個大研發平臺(如新型給藥系統、小分子創新等),在研產品包括OAB14(用於阿爾茨海默病治療)等多個1類創新藥物進展順利。未來公司將持續強化研發投入,依託院士團隊、校企合作等加快創新藥研發和新產品投產轉化,推動形成公司新的利潤增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.